NCT01211782
|
|
AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
|
Phase 2/Phase 3
|
Withdrawn
|
NCT02232152
|
2014-12-01 |
CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
|
Phase 1
|
Recruiting
|
NCT02168907
|
2014-12-01 |
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
|
Phase 1
|
Recruiting
|
NCT02168140
|
2014-09-01 |
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
|
Phase 1
|
Recruiting
|
NCT01864525
|
2013-07-01 |
Effects of Octanoic Acid for Treatment of Essential Voice Tremor
|
Phase 1/Phase 2
|
Recruiting
|
NCT01839981
|
2013-07-01 |
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 1
|
Recruiting
|
NCT01835041
|
2013-04-01 |
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
|
Phase 1
|
Recruiting
|
NCT01848327
|
2013-02-01 |
Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis
|
Phase 2
|
Recruiting
|
NCT01468948
|
2011-10-01 |
Octanoic Acid for Essential Tremor
|
Phase 1
|
Completed
|
NCT01110772
|
2009-05-01 |
Comparison of Iodine + Isopropyl Alcohol Versus Iodine + Antimicrobial Sealant for Skin Preparation
|
Phase 4
|
Recruiting
|
NCT00848172
|
2009-02-01 |
Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor
|
Phase 1/Phase 2
|
Completed
|